This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the HeartRhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024. EDT, in Rhythm Theater #2.
The international, multi-center trial will provide clinical evaluation of Cortex's 510(k) cleared Ablamap System with electrographic flow (EGF) and newly released Ablacath Mapping Catheter basket mapping catheter to identify extra-pulmonary vein EGF sources.
Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at HeartRhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment 8. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10.
Two articles and an accompanying editorial in HeartRhythm , the official journal of the HeartRhythm Society, the Cardiac Electrophysiology Society , and the Pediatric & Congenital Electrophysiology Society , published by Elsevier , address the controversy and recommend shortening the blanking period.
Pulsed-field energy ablation (PFA) was significantly associated with hemolysis compared to radiofrequency ablation (RFA) following pulmonary vein isolation (PVI), according to the results of a study presented at HeartRhythm 2024.
A company statement reported that its PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e.,
“It is exciting to see the convergence of our pioneering work in artificial intelligence and remote patient monitoring through this new partnership between Anumana and InfoBionic.Ai,” said Peter Noseworthy, MD, chair of the HeartRhythm Services Division of Cardiovascular Medicine at Mayo and a board director at InfoBionic.Ai. “By
CT of the chest showed no pulmonary embolism but bibasilar infiltrates. HeartRhythm [Internet]. (And of course Ken's comments at the bottom) An elderly obese woman with cardiomyopathy, Left bundle branch block, and chronic hypercapnea presented hypoxic with altered mental status. She was intubated. 2014;11:22732277.
male with pertinent past medical history including Atrial fibrillation, atrial flutter, cardiomyopathy, Pulmonary Embolism, and hypertension presented to the Emergency Department via ambulance for respiratory distress and tachycardia. He was noted to have irregular heartrhythm with rates 120-170s.
5 Catheter ablation is a safe and effective procedure when drugs don't work to help restore the heart's incorrect electrical signals, which causes an abnormal heartrhythm.6 2,3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib.4 1 These included one pseudoaneurysm, one PV stenosis and one hematoma.1
Early treatment of persistent AF can reduce the risk of blood clots, stroke, and heart failure, and may prevent the disease from becoming permanent. Patients are often treated with AADs as frontline therapy for heartrhythm maintenance, though some can experience adverse effects and limited efficacy.
Because the pulsed field energy is minimally thermal, IRE offers the potential to reduce the risk of damage to surrounding tissues including esophageal, pulmonary vein, and phrenic nerve injury. The Dual Energy STSF Catheter and the TruePulse Generator are under development and not available for sale in any region of the world.
During its Annual Conference, HRS 2024, the HeartRhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
Cardiomyopathy Cardiomyopathy is a condition that affects the heart muscle, causing it to become enlarged, thick, or rigid. This condition often leads to heart failure, as the heart cannot effectively pump blood. Beta-blockers , which slow the heart rate and reduce blood pressure. Anticoagulants to prevent blood clots.
The trial showed the Volt PFA System achieved pulmonary vein isolation (PVI) the method of destroying tissue causing a patient's AFib in 99.1% Volt PFA System PFA works differently from traditional ablation approaches by delivering high energy electrical pulses to targeted areas of cardiac tissue causing abnormal heartrhythms.
The VARIPULSE Platform is designed to enable pulmonary vein isolation with the versatility of a catheter loop, a simple generator user interface, and a mapping system that provides an intuitive, reproducible workflow with real-time visualization, contact indicator, and PF tagging mechanisms.
By continuously analyzing key health indicators such as irregular heartrhythms or respiratory rate changes AI can catch early warning signs that precede a cardiac episode.
Our mission to combat complex heartrhythm diseases relies on optimizing interoperability. The combined solutions are expected to enhance performance and streamline workflows for electrophysiologists during catheter ablation procedures to treat atrial fibrillation , AFib.
The PulseSelect PFA system was engineered with differentiated safety features and provides rapid, effective pulmonary vein isolation (PVI) through consistent and predictable energy delivery and catheter maneuverability. The system is designed to enable a seamless transition to PFA in a clinician's preferred workflow 2.
2** Furthermore, the primary effectiveness endpoint (PEE) of acute pulmonary vein isolation and 12-month freedom from atrial arrhythmia recurrence (AF, Atrial Tachycardia, or Atrial Flutter) was 75.6%. February 2–4; Boston [iv] British Heart Foundation. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation.
We assess dLVEDPs accuracy in predicting pulmonary capillary wedge pressure (PCWP) and propose a corrective equation.METHODS:We included 29 consecutive patients treated with Impella 5.5: performance level, heartrhythm, pacemaker settings, sex, mechanical ventilation, and body mass index were recorded.
Brugada Syndrome: Diagnosis and Risk Stratification Hello friends, this is the modified version of my talk at Indian HeartRhythm Society Conference, New Delhi, 2023, on Brugada Syndrome. HeartRhythm. Hope you will enjoy this session. 2016 Oct;13(10):e295-324. Francis J, Antzelevitch C. J Am Coll Cardiol.
“MANIFEST-17K provides confidence that, unlike conventional thermal ablation, PFA with the pentaspline catheter does not cause the most feared complication of AF ablation—esophageal damage—nor does it cause pulmonary vein stenosis or persistent injury to the diaphragm,” says senior author Vivek Reddy, MD , The Leona M. and Harry B.
Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)
The abnormal heartrhythms can further lead to death because of ventricular tachycardia and ventricular fibrillation. As a result, an ECG monitor is attached to the patient immediately upon arrival at the hospital to assess their heartrhythm and provide appropriate treatment in the event of an abnormal rhythm.
August 2024 Approvals Minima Stent System (P240003) (Approval Date: August 28, 2024) The Minima Stent System is an expandable cobalt-chromium metal mesh tube to reopen blood vessels in neonates, infants, and children with Coarctation of the Aorta and Pulmonary Artery Stenosis, specifically designed to expand as younger patients grow.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content